B, Immunoblot analysis of galectin-3,

E-cadherin and vill

B, Immunoblot analysis of galectin-3,

E-cadherin and villin normalized to the corresponding α-tubulin quantities. The results were analyzed using Student’s t-test. P < 0.001 was considered significant. (TIFF 567 KB) References 1. Waalkes S, Merseburger AS, Simon A, Serth J, Kuczyk MA: Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential. Urologe 2010, 49:387–391.PubMedCrossRef 2. Califice S, Castronovo V, van den Brule F: Galectin-3 and cancer (Review). Int J Oncol 2004, 25:983–992.PubMed 3. VandenBrule FA, Buicu C, Berchuck ABT-263 research buy A, Bast RC, Deprez M, Liu FT, Cooper DNW, Pieters C, Sobel ME, Castronovo V: Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. 3-Methyladenine supplier Human Pathology 1996, 27:1185–1191.CrossRef 4. Castronovo V, VandenBrule FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME: Decreased expression of

galectin-3 is associated with progression of human breast cancer. Journal of Pathology 1996, 179:43–48.PubMedCrossRef 5. Califice S, Castronovo V, Bracke M, van den Brule F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23:7527–7536.PubMedCrossRef 6. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 1998, 115:287–296.PubMedCrossRef 7. Lotz MM, Andrews CW, Korzelius Cell press CA, Lee EC, Steele GD, Clarke A, Mercurio AM: Decreased Expression of Mac-2 (Carbohydrate Binding Protein-35) and Loss of Its Nuclear-Localization Are Associated with the

Neoplastic Progression of Colon-Carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:3466–3470.PubMedCrossRef 8. Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, Nakatsuji H, Kanayama HO: Clinical Osimertinib order significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010, 57:152–157.PubMedCrossRef 9. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS: Expression profiling of renal epithelial neoplasms-A method for tumor classification and discovery of diagnostic molecular markers. American Journal of Pathology 2001, 158:1639–1651.PubMedCrossRef 10. Merseburger AS, Kramer MW, Hennenlotter J, Serth J, Kruck S, Gracia A, Stenzl A, Kuczyk M: Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World Journal of Urology 2008, 26:637–642.PubMedCrossRef 11. Francois C, van Velthoven R, De Lathouwer O, Moreno C, Peltier A, Kaltner H, Salmon I, Gabius HJ, Danguy A, Decaestecker C, Kiss R: Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. American Journal of Clinical Pathology 1999, 112:194–203.PubMed 12.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>